ICICI Securities Limited
Solara Active Pharma’s (Solara) Q2FY23 performance was below our estimates across all parameters.
Number of FII/FPI investors decreased from 75 to 67 in Mar 2025 qtr
More from Solara Active Pharma Sciences Ltd.
All Rapid Results
Recommended